⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
RIGL News
Rigel Pharmaceuticals Inc. (New)
Rigel Enters Exclusive Global Licensing Agreement for VEPPANU™ (vepdegestrant), an oral PROTAC, for the Treatment of 2L+ ER+/HER2-, ESR1m Advanced or Metastatic Breast Cancer
prnewswire.com
RIGL
Knight Therapeutics Announces Regulatory Approval of TAVALISSE® in Brazil
globenewswire.com
RIGL
Form 8-K
sec.gov
RIGL
Rigel Reports First Quarter 2026 Financial Results
prnewswire.com
RIGL
Form 8-K
sec.gov
RIGL
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
prnewswire.com
RIGL
Rigel Announces Publication of Final ARROW Clinical Trial Data on GAVRETO® (pralsetinib) in Patients with RET+ NSCLC in the Journal of Clinical Oncology
prnewswire.com
RIGL
Form 8-K
sec.gov
RIGL
Rigel Provides Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
prnewswire.com
RIGL
Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Ryan Maynard as Chief Financial Officer
globenewswire.com
FHTX
CRNX
RIGL